BioPharma Credit PLC (LSE: BPCR, ticker reference: BPCP), London's only specialist debt investment trust focused exclusively on the life sciences sector, has announced a new senior secured loan agreement with US biopharmaceutical company CorMedix Inc. The facility will see BPCR invest up to US$50 million alongside a parallel US$100 million commitment from BioPharma Credit Investments V (Master) LP, creating a total US$150 million facility. The investment is directly linked to CorMedix's planned acquisition of substantially all of Heron Therapeutics' assets, expected to close in Q1 2027, and represents a significant new deployment of capital for the trust's debt-focused strategy.

Key Points

  • BioPharma Credit PLC (LSE: BPCR; ticker reference: BPCP) is London's only specialist life sciences debt investment trust, admitted to the LSE in March 2017
  • BPCR has entered a senior secured loan agreement with CorMedix Inc. (NASDAQ: CRMD), committing up to US$50 million across two tranches of US$25 million each
  • The loan matures five years from first funding and carries interest at 3-month SOFR plus 5.75% per annum, subject to a 3.50% SOFR floor, with a 1.50% one-time fee per tranche
  • Investors should watch for confirmation of the Heron Acquisition closing in Q1 2027, which triggers Tranche A funding

BPCR's US$50 Million Commitment Forms Part of a US$150 Million Total Facility for CorMedix

BioPharma Credit PLC will invest its US$50 million through a fully owned subsidiary, acting also as collateral agent for the overall facility. The loan is structured in two tranches: Tranche A of US$25 million becomes available upon the closing of the Heron Acquisition, while Tranche B of up to US$25 million may be drawn until 30 June 2028 for the in-licensing or acquisition of additional commercial-stage pharmaceutical products. The loan will mature five years from the first funding date and bears interest at 3-month SOFR plus 5.75% per annum, subject to a 3.50% SOFR floor, with a 1.50% one-time additional consideration payable on each tranche at funding.

CorMedix's Acquisition of Heron Therapeutics' Assets Underpins the Loan Structure

On 9 November 2026, CorMedix announced a definitive asset purchase agreement with Heron Therapeutics, covering substantially all of Heron's assets, including four commercial-stage products: Zynrelef, Aponvie, Cinvanti, and Sustol. The upfront consideration comprises US$145 million in cash, subject to customary adjustments, plus 14,583,333 shares of CorMedix common stock. Additional earn-out payments of up to US$55 million are contingent on 2028 Zynrelef net sales, alongside a royalty on net sales of certain products. The transaction remains subject to regulatory clearance, Heron stockholder approval, and other customary closing conditions.

CorMedix Projects Combined Pro Forma Revenue of Up to US$490 Million Across 12 Commercial Products

CorMedix, which carries a current market capitalisation of approximately US$418 million, focuses on developing and commercialising therapeutic products for the prevention and treatment of life-threatening conditions in the United States. It operates through field-based medical and commercial infrastructure across hospitals, clinics, and infusion centres. According to CorMedix, the combined business following the Heron Acquisition is projected to generate pro forma 2026 estimated revenue of US$465 million to US$490 million across 12 commercial products, though this figure was provided by CorMedix and has not been independently verified in the announcement.

BPCR's Life Sciences Debt Strategy Targets Royalty and Cash-Flow-Secured Assets

BioPharma Credit PLC seeks to deliver long-term shareholder returns principally through sustainable income distributions, achieved by investing in debt assets secured by royalties or other cash flows derived from sales of approved life sciences products. This latest commitment to CorMedix aligns with that mandate, providing senior secured exposure to a borrower with an established commercial presence in institutional care settings across the United States. Investors in BPCR may be watching closely for the Q1 2027 closing of the Heron Acquisition, which is a key condition precedent to the first tranche being drawn and income from the new loan commencing.